Why GlaxoSmithKline plc, BT Group plc And Travis Perkins plc Offer Unmissable Value For Money!

Royston Wild explains why GlaxoSmithKline plc (LON: GSK), BT Group plc (LON: BT) and Travis Perkins plc (LON: TPK) all offer stonking bang for your buck.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at three of the hottest blue-chip bargains that London has to offer.

GlaxoSmithKline

I am convinced that medicines monster GlaxoSmithKline (LSE: GSK) provides brilliant growth and income prospects at an attractive price. The company has pulled out all the stops to kick-start its product pipeline and replace its ailing line of patent-related casualties like Advair, and GlaxoSmithKline currently has 40 new molecular entities (or NMEs) in late-stage testing.

The fruits of this hard work promise to deliver jumbo revenue growth in the years ahead, in my opinion, as a combination of rising populations and massive healthcare investment in emerging regions blasts global sales higher. As a result GlaxoSmithKline is anticipated to recover from a 21% earnings slippage this year to post a 12% rise in 2016, driving a P/E multiple of 17.2 times for 2015 to a very decent 15.5 times.

On top of this, GlaxoSmithKline’s vow to shell out a dividend of 80p per share through to the close of 2017 yields an impressive 6%, making mincemeat of the FTSE 100 average of 3.5%. With the business’ earnings outlook steadily improving, and the firm juggling its asset portfolio with the likes of Novartis to further boost the cash pile, I fully expect GlaxoSmithKline to meet these targets.

BT Group

The ‘quad-play’ entertainment sector has been one of the hottest plays in town in recent years — from Sky buying out its Italian and German arms, to Vodafone making its foray into the segment through the purchase of Kabel Deutschland and Spain’s Ono, companies the world over are betting big on this hot growth sector. With this in mind I believe BT Group (LSE: BT-A) is a great selection for clever investors.

BT has taken a shrewd approach to battling Sky by dismantling its stranglehold on British sports broadcasting, while the imminent launch of drama channel AMC Networks provides a credible alternative to its rival’s Sky Atlantic offering. With its fibre-laying drive also boosting broadband interest, the City expects BT to recover from a 3% earnings dip in the 12 months to March 2016 with a 7% recovery the following year.

Such figures result in ultra-low P/E ratios of 13.6 times and 12.8 times correspondingly, and the telecoms play’s bright profits outlook is predicted to keep dividends rising at breakneck speed, too. Last year’s reward of 12.4p per share is anticipated to rise to 14p in 2016 and 15.6p the following year, creating chunky yields of 3.3% and 3.7%.

Travis Perkins

Thanks to the buoyant construction market, I believe Travis Perkins (LSE: TPK) is a solid selection for those seeking great growth prospects. Indeed, a supportive industry backcloth has prompted the business to add a further 400 stores to its already-sprawling network in the next few years, thanks in no small part to resplendent activity across the housing sector.

And with the UK economy clicking steadily through the gears, I expect the top-line at Travis Perkins to keep on rocking. This view is shared by the City, and the retailer is expected to enjoy earnings growth of 9% in 2015 and 14% next year. As a result the stock sports terrific P/E multiples of 15.3 times and 13.4 times for 2015 and 2016 correspondingly.

In the medium term Travis Perkins is expected to lag the wider market in the dividend stakes, however — predicted payouts of 45.8p per share for 2015 and 54.4p for 2016 create handy, if unspectacular, yields of 2.3% and 2.7% respectively. But like BT, I believe investors should pay attention to the excellent growth rate in Travis Perkins’ annual dividend, a phenomenon that I expect to continue as earnings rocket higher.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman holding up three fingers
Investing Articles

Just released: our 3 top income-focused stocks to buy before December [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Up 125% in 5 years, the BAE share price has beaten Rolls-Royce. Which is better?

Both the BAE and Rolls-Royce share prices have been having a storming time. Here's how they stack up against each…

Read more »

Investing Articles

With P/E ratios of 7.2 and 9, I think these FTSE 100 shares are bargains!

The FTSE 100 has risen sharply in 2024, but there are still lots of top value shares out there. Royston…

Read more »

Investing Articles

This skyrocketing US growth stock has put all others to shame — including its core investment!

Up 378% this year, the spectacular growth of this US tech stock is leaving all others in the dust. But…

Read more »

Investing Articles

I’d buy this FTSE dividend share to target a lifelong second income

Our writer thinks investing in dividend stocks from the UK stock market is the best way for him to generate…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing For Beginners

The Barclays share price keeps surging! Was I wrong to sell the stock?

Jon Smith explains why the Barclays share price is still rising, even though he feels that further gains could be…

Read more »

Investing Articles

1 stock set to gatecrash the FTSE 100 in 2025!

Our writer considers a quality stock that's poised to join the FTSE 100 next year. Could there also be a…

Read more »

Businesswoman calculating finances in an office
Investing Articles

As earnings growth boosts the Imperial Brands share price, is it a top FTSE 100 dividend choice?

The Imperial Brands share price has come storming back as investors piled in for the big dividends. What's next, after…

Read more »